PIM
BBIO icon

Platinum Investment Management’s BridgeBio Pharma BBIO Stock Holding History

Platinum Investment Management’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.96M Sell
39,742
-9,527
-19% -$667K 0.73% 52
2026
Q1 		$3.66M Buy
49,269
+1,513
+3% +$110K 0.92% 41
2025
Q4 		$3.65M Sell
47,756
-14,488
-23% -$951K 0.84% 48
2025
Q3 		$3.23M Sell
62,244
-13,464
-18% -$657K 0.21% 50
2025
Q2 		$3.27M Buy
75,708
+5,358
+8% +$195K 0.22% 45
2025
Q1 		$2.43M Buy
+70,350
New +$2.37M 0.14% 50

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Platinum Investment Management's BBIO Position: Q2 2026 in Review

Platinum Investment Management reduced its BridgeBio Pharma (BBIO) stake by 19% in Q2 2026, selling an estimated $667K and leaving 39,742 shares worth $2.96M. The position accounts for 0.73% of the portfolio, ranked #52.

Platinum Investment Management first reported a position in BBIO in Q1 2025 and has held it in 6 quarters since. The position peaked at $3.66M in Q1 2026. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Platinum Investment Management held 39,742 shares of BridgeBio Pharma worth $2.96M as of Q2 2026.
  • Platinum Investment Management sold 9,527 BridgeBio Pharma shares in Q2 2026, an estimated $667K.
  • BridgeBio Pharma made up 0.73% of Platinum Investment Management's portfolio in Q2 2026, its #52 holding.
  • Platinum Investment Management first reported a position in BridgeBio Pharma in Q1 2025 and has held it in 6 quarters since.
  • Platinum Investment Management's BridgeBio Pharma position peaked at $3.66M in Q1 2026.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Platinum Investment Management's 13F filing for Q2 2026, filed 13 Aug 2026.